Navigation Links
BioMarin Announces Third Quarter 2009 Financial Results
Date:10/28/2009

fees (1) 1.4 - 1.4 8.8 1.4 8.8 Impairment charges (2) - - - 5.9 4.1 5.9 Kuvan Approval Milestones (3) (1.5) - (1.5) - (31.5) - Initial Aldurazyme transfer revenue (4) - - (2.3) - (2.3) - Net gain on the sale of equity investments - - - (1.6) - (1.6) Income tax effect of Non-GAAP adjustments (5) 0.1 - 0.2 0.3 2.2 0.3 --- --- --- --- --- --- Non-GAAP $39.8 to net income $8.2 $15.5 $21.9 $33.9 $30.0 43.8 ==== ===== ===== ===== ===== ===== Notes: (1) Represents upfront license payments related to our collaboration agreements with Summit Corporation plc and La Jolla Pharmaceutical Company in 2008 and 2009, respectively. (2) Includes impairment losses on investments in Summit plc. during the fourth quarter of 2008 and the first quarter of 2009, and La Jolla Pharmaceutical Company during the first quarter of 2009. (3) Represents approval milestones earned in July 2008 of $1.5 million for the Japanese approval of Kuvan and in December 2008 of $30.0 million for the EMEA approval of Kuvan. (4) Represents gross margin associated with the initial Aldurazyme product transfer to Genzyme of $2.3 million associated with the restructuring of BioMarin/Genzyme LLC in the first quarter of 2008. (5) Represents the tax effect of the adjustments. 
    Contact:

    Investors                          Media
    Eugenia Shen                       Susan Berg
    B
'/>"/>
SOURCE  BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 

Related medicine technology :

1. BioMarin to Present at the Oppenheimer Healthcare Conference
2. BioMarin Acquires Huxley Pharmaceuticals, Inc.
3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. BioMarin Announces FDA Approval for Kuvan
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Rigel Announces Presentations at Two Investor Conferences
10. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
11. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... According to Millennium Research Group (MRG), the global ... reforms in China supported rapid expansion of the ... continue to fuel growth in the coming years. ... Interventional Cardiology Devices 2010 report finds that ... the Chinese drug-eluting stent market to reach a ...
(Date:12/16/2009)... Greenway Medical Technologies, Inc. today announced ... (EHR), practice management and interoperability solution, Prime Suite® ... in the annual 2009 Top 20 Best ... report. ,, For practices having between six ... named Best in KLAS in ambulatory EMR for ...
(Date:12/16/2009)... /PRNewswire/ -- Sanofi Pasteur, the ... today that it has entered into an ... develop and commercialize its prophylactic vaccine against ... aureus or MRSA. MRSA are responsible ... referred to as multidrug-resistant Staphylococcus aureus ...
Breaking Medicine Technology:Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 2Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 4Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 2Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 3Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 4Hollis Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 14094 1Hollis Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 14094 2Hollis Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 14094 3Binghamton Research Group Develops New Cancer Treatment 5010 1Binghamton Research Group Develops New Cancer Treatment 5010 2Binghamton Research Group Develops New Cancer Treatment 5010 3Binghamton Research Group Develops New Cancer Treatment 5010 4Imaging features of intraductal papillary mucinous neoplasms of the pancreas 57344 1
... with tumor lysate,triggers robust antigen-specific CTL response", GAITHERSBURG, ... MaxCyte, Inc. and Medinet Co., Ltd. announce a,joint ... the,International Society for Cellular Therapy. The meeting is ... The presentation is entitled "Electroloading of mature dendritic,cells ...
... 2007 /PRNewswire-USNewswire/ -- Speaker,Nancy Pelosi issued the following ... the stem cell bill: , "Once again, the ... of leading medical researchers, and of a bipartisan,majority ... to the hopes of,million of families across America. ...
Other Medicine Technology:MaxCyte and Medinet to Present at the 13th Annual Meeting of the,International Society for Cellular Therapy (ISCT) in Sydney,Australia 2MaxCyte and Medinet to Present at the 13th Annual Meeting of the,International Society for Cellular Therapy (ISCT) in Sydney,Australia 3
(Date:12/16/2009)... seven that increase susceptibility to disease , , WEDNESDAY, ... with increased susceptibility to leprosy have been identified ... researchers, who analyzed more than 10,000 DNA samples ... said their discovery highlights the important role that ... of leprosy. , "Though leprosy is not common, ...
(Date:12/16/2009)... commonly found in fatty fish and algae help ... by the American Psychological Association. The finding connects ... people with schizophrenia; bipolar, obsessive-compulsive, and attention-deficit hyperactivity ... nervous system. , The study, reported in ... evidence that fish is brain food. The key ...
(Date:12/16/2009)... of Digital Pen and Paper technology and the provider of ... announced that it is ranked among the Fastest Growing Technology ... , ... (PRWEB) December 16, 2009 ... the capture, digitalization and management of handwritten data. Kayentis targets ...
(Date:12/16/2009)... all-time low, government report shows, , , WEDNESDAY, Dec. 16 ... States has reached almost 78 years, a record high, ... 2007, women can expect to live to 80.4 years ... the report from the U.S. Centers for Disease Control ... expect to live longer than their parents, life expectancy ...
(Date:12/16/2009)... 16 New research published online, ... in pistachios, and molecules present in pistachios, ... decreases levels of an inflammatory marker known ... 2). Inflammation is a complex biological response ... irritants, and it underlies functional changes associated ...
Breaking Medicine News(10 mins):Health News:Leprosy Genes Identified 2Health News:New study links DHA type of omega-3 to better nervous-system function 2Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 3
... under spotlight following a consumer survey which found evidence ... NHS facilities. ,A review of hospital hygiene ... in Ulster, over the past three years by the ... kitchens in addition to lack of soap and hot ...
... enhance the risk of colorectal cancer in laboratory mice which ... colon cancer in humans, according to a study by Canadian ... one-year study of 137 mice, saw that animals that were ... likelihood of developing colorectal cancer than rodents which were given ...
... ownership of the health trust in the North West will ... cash so raised will be ploughed back to uplift healthcare ... muster about ?10,000 a year through the leasing of 60 ... hospital. ,Joanne Quinn, Head of Corporate Affairs at ...
... insurance industry in India is still lurching under problems ... not ready to risk the cost of delivery of ... experts., ,These issues pertaining to the health insurance ... Micro Health Insurance: Developing Pro-Poor Health Insurance in India, ...
... the ban on mercury based flu vaccines given to pregnant ... six weeks . This decision was made due to a ... free children's vaccine is manufactured by Sanofi pasteur, and the ... speed up production to meet the state's need. ,The ...
... A new artificial pump along with the intake of certain ... itself, say scientists in Britain.// ,The temporary pumps, ... in patients with severe heart failure while they await transplantation, ... takes on the work of one of the heart's four ...
Other Medicine News:Health News:Poor Hygiene in Ulster Hospital Kitchens 2Health News:Colon cancer Linked to low-folate diet 2Health News:Colon cancer Linked to low-folate diet 3Health News:New Device May Help Heal A Failing Heart 2
... Consolidated Workstation to Automate Deparaffinization, FISH ... you can perform deparaffinization, pretreatment, histology/cytology ... slide washing with a single system... ... Vysis protocols for fluorescence in situ ...
... The Abbott m1000 sample preparation platform ... extract RNA and DNA from patient samples ... high throughput, fully automated sample preparation and ... approximately 2 hours for a 1 ml ...
... the power of multiple technologies to ... hematology laboratory. Fluorescent detection of RNA ... Fluorescent DNA staining of nucleated red ... cell values and provides a reportable ...
... The CELL-DYN 3200 sets a benchmark ... light scatter for WBC, RBC, PLT ... meets the needs of today's laboratory. ... five-part differential analysis, automated sample handling, ...
Medicine Products: